Multiple Sclerosis

Two case reports of rare stiff person syndrome

Two female patients achieved clinical remission from the rare, debilitating neurological disease called stiff person syndrome (SPS, which can be marked by a "tin soldier" gait) after an autologous (from your own body) stem ...

Aug 25, 2014
popularity 5 / 5 (1) | comments 0

Balance impairment in MS involves multiple systems

(HealthDay)—Balance impairment in multiple sclerosis (MS) involves constraints across multiple systems and consequently necessitates multimodal treatment, according to a study published in the September ...

Sep 26, 2014
popularity 5 / 5 (1) | comments 0

Group exercise crucial for people with MS

(Medical Xpress)—Group exercise should become a standard health practice in South Australia's public health system to provide much-needed support for people with multiple sclerosis (MS), Flinders University ...

Jun 19, 2014
popularity 4 / 5 (1) | comments 0

Latest Spotlight News

Stroke damage mechanism identified

Researchers have discovered a mechanism linked to the brain damage often suffered by stroke victims—and are now searching for drugs to block it.

Berberine compound may play role in treating obesity

(Medical Xpress)—Weight-gain warnings are especially uncomfortable during holiday seasons with all the oversized and double helpings of calorie-rich pies, creamy dips and savory holiday stuffings. Nonetheless, ...

"Body recognition" compares with fingerprint ID

(Medical Xpress)—University of Adelaide forensic anatomy researchers are making advances in the use of "body recognition" for criminal and missing persons cases, to help with identification when a face ...

Some people may be pre-wired to be bilingual

(HealthDay)—Some people's brains seem pre-wired to acquire a second language, new research suggests. But anyone who tries to move beyond their mother tongue will likely gain a brain boost, the small study ...

Ebola vaccine promising in first human trials

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.